Want to see FTRE full AI Analyst Report?
FTRE Stock Chart & Stats
$10.38
-$0.82(-4.27%)
At close: 4:00 PM EST
$10.38
-$0.82(-4.27%)
Day’s Range― - ―
52-Week Range$4.46 - $18.67
Previous CloseN/A
Volume188.47K
Average Volume (3M)1.80M
Market Cap
$1.68B
Enterprise Value$2.42B
Total Cash (Recent Filing)$147.50M
Total Debt (Recent Filing)$1.12B
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Aug 17, 2026EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.93
Shares Outstanding94,600,000
10 Day Avg. Volume2,205,510
30 Day Avg. Volume1,801,545
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.79
Price to Sales (P/S)0.58
P/FCF Ratio17.82
Enterprise Value/Market Cap1.44
Enterprise Value/Revenue0.89
Enterprise Value/Gross Profit5.59
Enterprise Value/Ebitda-8.61
Forecast
1Y Price Target
$15.64Price Target Upside50.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)0.81
Revenue Forecast (FY)$2.61B
Bulls Say, Bears Say
Bulls Say
Backlog & Book-to-billA $7.8B backlog and a Q1 book-to-bill of 1.15x provide durable revenue visibility and show improving sales execution. Large contracted work smooths near-term volatility, supports multi-quarter revenue run-rate, and underpins recovery efforts while management executes efficiency plans.
Strong Cash Generation And Low LeverageConsistent positive TTM operating and free cash flow alongside low debt-to-equity (~0.14) and >$0.5B liquidity give Fortrea financial flexibility. This cash cushion supports reinvestment, debt reduction and funding of margin initiatives, making capital structure resilient over the medium term.
Technology Differentiation (FIT)The FIT AI-enabled platform is a structural capability that can boost efficiency, trial execution speed and win rates over time. As adoption scales, FIT could drive durable margin improvement and competitive differentiation across integrated clinical development services.
Bears Say
Sharp Revenue Decline & Weak MarginsA ~54% TTM revenue drop and compressed gross margins (~16%) with ongoing net losses indicate impaired earnings power. Sustained margin pressure and negative ROE reduce internal capacity to fund growth, making profit recovery and durable shareholder value dependent on meaningful structural revenue improvement.
Customer ConcentrationOver half of revenue from the top 10 clients creates persistent concentration risk. Large clients have leverage to demand price concessions or change scopes; any slowdown or loss at a top account can materially swing results and limit pricing power across contract negotiations.
FSP/pass-through Headwinds & Pricing ConcessionsEmbedded rate-card concessions on FSP work and lower pass-through topline reduce revenue and margin sustainably if pervasive. These contract-level effects alter backlog burn and limit near-term top-line growth, complicating the path to mid‑teens adjusted EBITDA unless offset by new wins or structural pricing recovery.
Fortrea Holdings Inc. News
FTRE FAQ
What was Fortrea Holdings Inc.’s price range in the past 12 months?
Fortrea Holdings Inc. lowest stock price was $4.46 and its highest was $18.67 in the past 12 months.
What is Fortrea Holdings Inc.’s market cap?
Fortrea Holdings Inc.’s market cap is $1.68B.
When is Fortrea Holdings Inc.’s upcoming earnings report date?
Fortrea Holdings Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 35 days.
How were Fortrea Holdings Inc.’s earnings last quarter?
Fortrea Holdings Inc. released its earnings results on May 05, 2026. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.061 by $0.099.
Is Fortrea Holdings Inc. overvalued?
According to Wall Street analysts Fortrea Holdings Inc.’s price is currently Undervalued.
Does Fortrea Holdings Inc. pay dividends?
Fortrea Holdings Inc. does not currently pay dividends.
What is Fortrea Holdings Inc.’s EPS estimate?
Fortrea Holdings Inc.’s EPS estimate is 0.18.
How many shares outstanding does Fortrea Holdings Inc. have?
Fortrea Holdings Inc. has 94,600,000 shares outstanding.
What happened to Fortrea Holdings Inc.’s price movement after its last earnings report?
Fortrea Holdings Inc. reported an EPS of $0.16 in its last earnings report, beating expectations of $0.061. Following the earnings report the stock price went up 18.612%.
Which hedge fund is a major shareholder of Fortrea Holdings Inc.?
Currently, no hedge funds are holding shares in FTRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fortrea Holdings Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.64 (50.70% Upside)
$15.64 (50.70% Upside)
Hedge Fund Trend
Increased
By 357.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $105.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.29%
12-Months-Change
Fundamentals
Return on Equity
-79.12%
Trailing 12-Months
Asset Growth
-14.02%
Trailing 12-Months
Company Description
Fortrea Holdings Inc.
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
FTRE Stock 12 Month Forecast
Average Price Target
$15.64
▲(50.70% Upside)
Technical Analysis
Nektar Therapeutics
―
Fulcrum Therapeutics
―
Compass Therapeutics
―
Erasca
―
Aura Biosciences Inc
―
Ownership Overview
0.72% Insiders
20.79% Mutual Funds
0.35% Other Institutional Investors
47.48% Public Companies and
Individual Investors










